Skip to content
2000
Volume 18, Issue 1
  • ISSN: 2589-9775
  • E-ISSN: 2589-9783

Abstract

Introduction

Escalating healthcare costs and increasing demands on healthcare systems have increased the need for efficient resource allocation. Pharmacoeconomics is a vital field that quantifies and compares the value of therapeutic drugs or treatments. It provides a systematic framework for decision-makers in the pharmaceutical industry, government, and private sectors to optimize healthcare delivery and spending. This review aimed to explore the role of pharmacoeconomic models in assessing the economic and clinical value of therapies. It emphasizes the importance of cost-effectiveness, cost-utility, cost-benefit, and cost-minimization analyses in balancing costs with outcomes and guiding healthcare resource allocation.

Methods

Pharmacoeconomic methodologies focus on assessing the costs, processes, and outcomes associated with therapeutic interventions. Key methods include cost-minimization, cost-effectiveness, cost-utility, and cost-benefit analyses. These approaches are critical in regulatory compliance, reimbursement decisions, cost assessments, and sustaining pharmaceutical models.

Results

This review reveals that pharmacoeconomic approaches such as Cost-Effectiveness Analysis (CEA), Cost-Utility Analysis (CUA), and Cost-Benefit Analysis (CBA) are widely used to guide healthcare policy decisions, particularly in resource-constrained settings. CEA is the most commonly applied method due to its simplicity, while CUA is gaining traction in advanced policy frameworks like Health Technology Assessment (HTA). In India, pharmacoeconomic research is emerging but faces barriers such as limited access to real-world data, the absence of national reimbursement systems, and high out-of-pocket costs. Innovative methods like machine learning and pharmacogenomics are being explored to improve the relevance and precision of these evaluations.

Discussion

While pharmacoeconomic models offer valuable insights for healthcare decision-making, their real-world impact is limited by inconsistencies in data quality and variations in implementation standards. In India, fragmented governance, low public health spending, and a lack of coordination among stakeholders further hinder effective application. Addressing systemic challenges-such as establishing interoperable data systems, standard treatment guidelines, and equitable healthcare access-is crucial. Tailored approaches, including localized utility values and digital health initiatives, are essential to make pharmacoeconomics a practical and influential tool in policy formulation and resource allocation in India and similar settings.

Conclusion

Pharmacoeconomic studies evaluate clinical efficacy, adverse effects, and production costs while incorporating perspectives from patients, providers, payers, and communities. For India, unique challenges such as limited rural healthcare access, infrastructure disparities, and high out-of-pocket expenses necessitate tailored adaptations. Strategies such as integrating accessibility metrics, localized data, equity considerations, preventive care, tiered pricing, and public-private partnerships can enhance healthcare delivery. Pharmacoeconomic models are essential for improving health outcomes, ensuring equitable resource allocation, and addressing the diverse needs of India.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdrr/10.2174/0125899775394503250626070441
2025-07-04
2026-02-25

  • From This Site

    /content/journals/cdrr/10.2174/0125899775394503250626070441
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Arenas-GuzmanR TostiA HayR HanekeE. Pharmacoeconomics - An aid to better decision‐making. J Eur Acad Dermatol Venereol 2005; 19(s1): 34-9.(Suppl. 1)10.1111/j.1468‑3083.2005.01285.x 16120204
     [Google Scholar]
  2. ToninF.S. Aznar-LouI. PontinhaV.M. PontaroloR. Fernandez-LlimosF. Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions.Pharm. Pract.2021191230210.18549/PharmPract.2021.1.2302 33727994
     [Google Scholar]
  3. DaviesB. Responsibility and the limits of patient choice.Bioethics202034545946610.1111/bioe.12693 31770814
     [Google Scholar]
  4. HumphreysP. SprattB. TariverdiM. An overview of hospital capacity planning and optimisation.Health care202210582610.3390/healthcare10050826 35627963
     [Google Scholar]
  5. PicotJ. JonesJ. ColquittJ.L. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: A systematic review and economic evaluation.Health Technol. Assess.200913411190, 215-357iii-iv10.3310/hta13410 19726018
     [Google Scholar]
  6. LovemanE. FramptonG.K. ShepherdJ. The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: A systematic review.Health Technol. Assess.2011152118210.3310/hta15020 21247515
     [Google Scholar]
  7. RodziewiczT.L. HousemanB. VaqarS. Medical Error Reduction and Prevention.Treasure Island, FLStatPearls Publishing2025
     [Google Scholar]
  8. AhmadA. ChangJ. ChungH.C. MohantaG. ParimilakrishnanS. PatelI. The role of pharmacoeconomics in current Indian healthcare system.J. Res. Pharm. Pract.2013213910.4103/2279‑042X.114081 24991597
     [Google Scholar]
  9. Satya DurgaK. SowmyaN. CharishmaS. Sharmila NirojiniP. A pharmacoeconomic study and its appraisal in improving health care outcomes in patients suffering from type-2 diabetes among rural areas in South-East India.Int. J. Adv. Res.2017589090110.21474/IJAR01/6035
     [Google Scholar]
  10. ThwaitesR. TownsendR.J. Pharmacoeconomics in the new millennium. A pharmaceutical industry perspective.PharmacoEconomics199813217518010.2165/00019053‑199813020‑00002 10178645
     [Google Scholar]
  11. ReederCE Overview of pharmacoeconomics and pharmaceutical outcomes evaluations. Am J Health Syst Pharm19955219S5-8.(Suppl. 4)10.1093/ajhp/52.19_Suppl_4.S5 8846244
     [Google Scholar]
  12. BodrogiJ. KalóZ. Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development.Br. J. Pharmacol.201015971367137310.1111/j.1476‑5381.2009.00550.x 20132213
     [Google Scholar]
  13. ThomasR. ChalkidouK. Health system efficiency: How to make measurement matter for policy and management.In: Cost–effectiveness analysis.Copenhagen (Denmark)European Observatory on Health Systems and Policies2016
     [Google Scholar]
  14. FanC. SongX. LiC. The relationship between health insurance and pharmaceutical innovation: An empirical study based on meta-analysis.Health care20231122291610.3390/healthcare11222916 37998407
     [Google Scholar]
  15. LangleyP.C. SullivanS.D. Pharmacoeconomic evaluations: Guidelines for drug purchasers.J. Manag. Care Spec. Pharm.202026668969510.18553/jmcp.2020.26.6.689 32463775
     [Google Scholar]
  16. FreundD.A. DittusR.S. Principles of pharmacoeconomic analysis of drug therapy.PharmacoEconomics199211203210.2165/00019053‑199201010‑00006 10147037
     [Google Scholar]
  17. DrummondM. JönssonB. RuttenF. The role of economic evaluation in the pricing and reimbursement of medicines.Health Policy199740319921510.1016/S0168‑8510(97)00901‑9 10168752
     [Google Scholar]
  18. HusseyP.S. WertheimerS. MehrotraA. The association between health care quality and cost: A systematic review.Ann. Intern. Med.20131581273410.7326/0003‑4819‑158‑1‑201301010‑00006 23277898
     [Google Scholar]
  19. GoldH.T. McDermottC. HoomansT. WagnerT.H. Cost data in implementation science: Categories and approaches to costing.Implement. Sci.20221711110.1186/s13012‑021‑01172‑6 35090508
     [Google Scholar]
  20. ShiN. FoleyK. LenhartG. BadamgaravE. Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures.Bone20094561084109010.1016/j.bone.2009.07.086 19664735
     [Google Scholar]
  21. StahlJ.E. Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide.PharmacoEconomics200826213114810.2165/00019053‑200826020‑00004 18198933
     [Google Scholar]
  22. KozmaC.M. ReederC.E. SchulzR.M. Economic, clinical, and humanistic outcomes: A planning model for pharmacoeconomic research.Clin. Ther.199315611211132 8111809
     [Google Scholar]
  23. PrinjaS. ChauhanA.S. AngellB. GuptaI. JanS. A systematic review of the state of economic evaluation for health care in India.Appl. Health Econ. Health Policy201513659561310.1007/s40258‑015‑0201‑6 26449485
     [Google Scholar]
  24. HughesD.A. An agenda for UK clinical pharmacology: Pharmacoeconomics.Br. J. Clin. Pharmacol.201273696897210.1111/j.1365‑2125.2012.04247.x 22360714
     [Google Scholar]
  25. RevickiD.A. LuceB.R. Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry.Psychopharmacol. Bull.19953115765 7675990
     [Google Scholar]
  26. DrummondM.F. StoddartG.L. TorranceG.W. Methods for the Economic Evaluation of Health Care Programmes.2nd edOxfordOxford University Press1997
     [Google Scholar]
  27. SacristánJ.A. SotoJ. GalendeI. Evaluation of pharmacoeconomic studies: Utilization of a checklist.Ann. Pharmacother.19932791126113310.1177/106002809302700919 8219449
     [Google Scholar]
  28. HaycoxA. WalleyT. Pharmacoeconomics: Evaluating the evaluators.Br. J. Clin. Pharmacol.199743545145610.1046/j.1365‑2125.1997.00575.x 9159558
     [Google Scholar]
  29. JolicoeurL.M. Jones-GrizzleA.J. BoyerJ.G. Guidelines for performing a pharmacoeconomic analysis.Am. J. Hosp. Pharm.199249717411747 1621734
     [Google Scholar]
  30. LongoCJ Choices of methodology in pharmacoeconomics studies. Med Care 1999; 37(4 Suppl Lilly): AS32-5.10.1097/00005650‑199904001‑00006 10217391
     [Google Scholar]
  31. PlumridgeR.J. Wojnar-HortonR.E. A review of the pharmacoeconomics of pharmaceutical care.PharmacoEconomics199814217518910.2165/00019053‑199814020‑00006 10186458
     [Google Scholar]
  32. WalleyT. HaycoxA. Pharmacoeconomics: Basic concepts and terminology.Br. J. Clin. Pharmacol.199743434334810.1046/j.1365‑2125.1997.00574.x 9146844
     [Google Scholar]
  33. MullinsC.D. WangJ. Pharmacy benefit management: Enhancing the applicability of pharmacoeconomics for optimal decision making.PharmacoEconomics200220192110.2165/00019053‑200220010‑00002 11817989
     [Google Scholar]
  34. DuggalR. Healthcare in India: Changing the financing strategy.Soc. Policy Adm.200741438639410.1111/j.1467‑9515.2007.00560.x
     [Google Scholar]
  35. KumarR. DuggiralaA. Health insurance as a healthcare financing mechanism in India: Key strategic insights and a business model perspective.Vikalpa202146211212810.1177/02560909211027089
     [Google Scholar]
  36. KumarA. The transformation of the indian healthcare system.Cureus20231553907910.7759/cureus.39079 37378105
     [Google Scholar]
  37. BalarajanY. SelvarajS. SubramanianS.V. Health care and equity in India.Lancet2011377976450551510.1016/S0140‑6736(10)61894‑6 21227492
     [Google Scholar]
  38. KadarpetaR.S.R. AnandJ.S. AchunguraG. Strengthening public financing of primary healthcare in India: A perspective.Health Serv. Insights2024171178632924124928910.1177/11786329241249289 38737570
     [Google Scholar]
  39. BoseM. DuttaA. Health financing strategies to reduce out-of-pocket burden in India: A comparative study of three states.BMC Health Serv. Res.201818183010.1186/s12913‑018‑3633‑5 30390701
     [Google Scholar]
  40. MauryaD. AsherM. Sustainable health financing system for India: The economic perspective.Natl. Med. J. India2021342959910.4103/0970‑258X.326759 34599122
     [Google Scholar]
  41. HendrixN. KweteX. BolongaitaS. Economic evaluations of health system strengthening activities in low-income and middle-income country settings: A methodological systematic review.BMJ Glob. Health20227300739210.1136/bmjgh‑2021‑007392 35277429
     [Google Scholar]
  42. TarnYH HuS KamaeI Health-care systems and pharmacoeconomic research in Asia-Pacific region.Value Health200811: S137-55.(Suppl. 1)10.1111/j.1524‑4733.2008.00378.x 18387058
     [Google Scholar]
  43. AgrawalS.B. Health technology assessment in India: Present status and future perspectives.J. Adv. Pharm. Educ. Res.2014411319
     [Google Scholar]
  44. ParthasarathiG. Nyfort-HansenK. NahataM.C. A Textbook of Clinical Pharmacy Practice, Essential Concepts and Skills.Orient Blackswan2007
     [Google Scholar]
  45. McGhanW.F. RowlandC.R. BootmanJ.L. Cost-benefit and cost-effectiveness: Methodologies for evaluating innovative pharmaceutical services.Am. J. Health Syst. Pharm.197835213314010.1093/ajhp/35.2.133 415603
     [Google Scholar]
  46. Lyle BootmanJ. WertheimerA.I. ZaskeD. RowlandC. Individualizing gentamicin dosage regimens in burn patients with gram-negative septicemia: A cost-benefit analysis.J. Pharm. Sci.197968326727210.1002/jps.2600680304 106108
     [Google Scholar]
  47. Guidelines for the pharmaceutical industry on preparation of submission to the pharmaceutical benefits advisory committee.1992Available from: www.health.gov.au/pbs/pharm/pubs/guidelines/content.html
  48. Drug and Therapeutic Committees: A practical guide, managing the formulary process.2003Available from: http://www.apps.who.int/medicinedocs/en/d/Js4882e/5.html
    [Google Scholar]
  49. TrudeS. AuM. ChristiansonJ.B. Health plan pay-for-performance strategies.Am. J. Manag. Care2006129537542 16961442
     [Google Scholar]
  50. JadaunG.P.S. RastogiS. KumarA. Ensuring the quality of medicines in India: An update on the development, modernization, and harmonization of drug standards in the Indian Pharmacopoeia.Saudi Pharm. J.2023311210182510.1016/j.jsps.2023.101825 37965488
     [Google Scholar]
  51. TenniB. MoirH.V.J. TownsendB. What is the impact of intellectual property rules on access to medicines? A systematic review.Global. Health20221814010.1186/s12992‑022‑00826‑4 35428250
     [Google Scholar]
  52. ParkY. RazaS. GeorgeA. AgrawalR. KoJ. The effect of formulary restrictions on patient and payer outcomes: A systematic literature review.J. Manag. Care Spec. Pharm.201723889390110.18553/jmcp.2017.23.8.893 28737993
     [Google Scholar]
  53. ParrishR.H. Lecture 2—What is a formulary, anyway? (or the cliff notes version of drug stewardship and expense control).Pharmacy2018636910.3390/pharmacy6030069 30036933
     [Google Scholar]
  54. AlzareaA.I. KhanY.H. AlanaziA.S. Barriers and facilitators of pharmacoeconomic studies: A review of evidence from the middle eastern countries.Int. J. Environ. Res. Public Health20221913786210.3390/ijerph19137862 35805521
     [Google Scholar]
  55. WaltG. ShiffmanJ. SchneiderH. MurrayS.F. BrughaR. GilsonL. ‘Doing’ health policy analysis: Mthodological and conceptual reflections and challenges.Health Policy Plan.200823530831710.1093/heapol/czn024 18701552
     [Google Scholar]
  56. Institute of Medicine (US) Committee on the Social and Ethical Impacts of Developments in Biomedicine.1995Available from: https://www.ncbi.nlm.nih.gov/books/NBK231979/
  57. Health policy and management. Wikipedia, The Free Encyclopedia. 2023. Available fromhttps://en.wikipedia.org/w/index.php?title=Health_policy_and_management&oldid=1184041095
  58. OjhaA. OjhaU. OjhaH. Role of AYUSH therapies in modern medicine: A qualitative study to explore the awareness and attitudes of doctors towards the utilization of alternate system of medicine for diabetes mellitus.Int. J. Gen. Med.2020131810.2147/IJGM.S220444 32021386
     [Google Scholar]
  59. MilewskaS. Niemirowicz-LaskowskaK. SiemiaszkoG. NowickiP. WilczewskaA.Z. CarH. Current trends and challenges in pharmacoeconomic aspects of nanocarriers as drug delivery systems for cancer treatment.Int. J. Nanomedicine2021166593664410.2147/IJN.S323831 34611400
     [Google Scholar]
  60. RusmawantiaD.A. WijayaH. CitraningtyasG. Al-MubarakA. Pharmacists’ knowledge of non-sterile good compounding practice (GCP) and its implementation in balikpapan community health centers: A cross-sectional study.Malays J Med Res202591112110.31674/mjmr.2025.v09i01.002
     [Google Scholar]
  61. JohnsonS.G. SimonG. AliferisC. Artificial Intelligence and Machine Learning in Health Care and Medical Sciences: Best Practices and Pitfalls.Cham, CHSpringer202465969210.1007/978‑3‑031‑39355‑6_16
     [Google Scholar]
  62. McCombsJ. Pharmacoeconomics: What is it and where is it going?Am. J. Hypertens.1998113112S119S10.1016/S0895‑7061(98)00108‑3 9717852
     [Google Scholar]
  63. D’ErricoC.C. Pharmacoeconomics analysis in a pediatric population.Ann. Thorac. Surg.1998656S52S55(Suppl.)10.1016/S0003‑4975(98)00331‑2 9647139
     [Google Scholar]
  64. ZhengY. PanF. SorensenS. Modeling treatment sequences in pharmacoeconomic models.PharmacoEconomics2017351152410.1007/s40273‑016‑0455‑3 27722894
     [Google Scholar]
  65. CartaA. ConversanoC. On the use of markov models in pharmacoeconomics: Pros and cons and implications for policy makers.Front. Public Health2020856950010.3389/fpubh.2020.569500 33194969
     [Google Scholar]
  66. BriggsA. SculpherM. An introduction to Markov modelling for economic evaluation.PharmacoEconomics199813439740910.2165/00019053‑199813040‑00003 10178664
     [Google Scholar]
  67. WelsingP.M.J. SeverensJ.L. HartmanM. van GestelA.M. van RielP.L.C.M. LaanR.F.J.M. The initial validation of a Markov model for the economic evaluation of (new) treatments for rheumatoid arthritis.PharmacoEconomics200624101011102010.2165/00019053‑200624100‑00008 17002483
     [Google Scholar]
  68. NuijtenM.J.C. van IperenP. PalmerC. van HiltenB.J. SnyderE. Cost-effectiveness analysis of entacapone in Parkinson’s disease: A Markov process analysis.Value Health20014431632810.1046/j.1524‑4733.2001.004004316.x 11705299
     [Google Scholar]
  69. PolakS. SkowronA. MendykA. BrandysJ. Artificial neural network in pharmacoeconomics.Stud. Health Technol. Inform.2004105241249 15718613
     [Google Scholar]
  70. YagudinaR. KulikovA. SerpikV. BorodinA. VygodchikovaI. Patient flows, patient distribution computations and medicines accounting in the pharmacoeconomic models through procurement perspective.Clinicoecon. Outcomes Res.20211367368010.2147/CEOR.S312986 34326653
     [Google Scholar]
  71. MillerP. Role of pharmacoeconomic analysis in R&D decision making: When, where, how?PharmacoEconomics200523111210.2165/00019053‑200523010‑00001 15693724
     [Google Scholar]
  72. van BaalP. MeltzerD. BrouwerW. Pharmacoeconomic guidelines should prescribe inclusion of indirect medical costs! A response to Grima et Al.PharmacoEconomics201331536937310.1007/s40273‑013‑0042‑9 23595557
     [Google Scholar]
  73. AgroK.E. BradleyC.A. MittmannN. IskedjianM. IlersichA.L. EinarsonT.R. Sensitivity analysis in health economic and pharmacoeconomic studies. An appraisal of the literature.PharmacoEconomics1997111758810.2165/00019053‑199711010‑00009 10165529
     [Google Scholar]
  74. JainR. GrabnerM. OnukwughaE. Sensitivity analysis in cost-effectiveness studies: From guidelines to practice.PharmacoEconomics201129429731410.2165/11584630‑000000000‑00000 21395350
     [Google Scholar]
  75. BaeS. LeeJ. BaeE.Y. How sensitive is sensitivity analysis?: Evaluation of pharmacoeconomic submissions in Korea.Front. Pharmacol.20221388476910.3389/fphar.2022.884769 35652044
     [Google Scholar]
  76. BriggsA. SculpherM. Sensitivity analysis in economic evaluation: A review of published studies.Health Econ.19954535537110.1002/hec.4730040502 8563834
     [Google Scholar]
  77. NuijtenM.J.C. HardensM. Measuring sensitivity in pharmacoeconomic studies. An integration of point-sensitivity and range-sensitivity.PharmacoEconomics199712555556410.2165/00019053‑199712050‑00006 10174322
     [Google Scholar]
  78. VremanR.A. GeenenJ.W. KniesS. Mantel-TeeuwisseA.K. LeufkensH.G.M. GoettschW.G. The application and implications of novel deterministic sensitivity analysis methods.PharmacoEconomics202139111710.1007/s40273‑020‑00979‑3 33313990
     [Google Scholar]
  79. WaniN.U. TanejaK. AdlakhaN. Health system in India: Opportunities and challenges for enhancements.IOSR J. Bus. Manag.2013927482
     [Google Scholar]
  80. MorganS ThomsonPA DawJR FriesenMK DijkstraA The public provision of pharmaceuticals: A synthesis of policies in ten developed countries.
     [Google Scholar]
  81. KoopmanschapM.A. RuttenF.F.H. The impact of indirect costs on outcomes of health care programs.Health Econ.19943638539310.1002/hec.4730030606 9435921
     [Google Scholar]
  82. FuscoN. SilsB. GraffJ.S. KistlerK. RuizK. Cost-sharing and adherence, clinical outcomes, health care utilization, and costs: A systematic literature review.J. Manag. Care Spec. Pharm.202329141610.18553/jmcp.2022.21270 35389285
     [Google Scholar]
  83. MartinS. RiceN. SmithP.C. Comparing costs and outcomes across programmes of health care.Health Econ.201221331633710.1002/hec.1716 21322086
     [Google Scholar]
  84. LavtepatilS. GhoshS. Improving access to medicines by popularising generics: A study of ‘India’s People’s Medicine’ scheme in two districts of Maharashtra.BMC Health Serv. Res.202222164310.1186/s12913‑022‑08022‑1 35562697
     [Google Scholar]
  85. CharanJ. SaxenaD. ChaudhriM. DuttaS. KaurR.J. BhardwajP. Opinion of primary care physicians regarding prescription of generic drugs.J. Family Med. Prim. Care20211031390139810.4103/jfmpc.jfmpc_2157_20 34041184
     [Google Scholar]
  86. LiR ZhangP BarkerLE ChowdhuryFM ZhangX Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care201033818729410.2337/dc10‑0843 20668156
     [Google Scholar]
  87. AnawadeP.A. SharmaD. GahaneS. A comprehensive review on exploring the impact of telemedicine on healthcare accessibility.Cureus20241635599610.7759/cureus.55996 38618307
     [Google Scholar]
  88. GizawZ. AstaleT. KassieG.M. What improves access to primary healthcare services in rural communities? A systematic review.BMC Primary Care202223131310.1186/s12875‑022‑01919‑0 36474184
     [Google Scholar]
  89. GhiaC. RambhadG. Implementation of equity and access in Indian healthcare: Current scenario and way forward.J. Mark. Access Health Policy2023111219450710.1080/20016689.2023.2194507 36998432
     [Google Scholar]
  90. MohantyS.K. UpadhyayA.K. MaitiS. Public health insurance coverage in India before and after PM-JAY: Repeated cross-sectional analysis of nationally representative survey data.BMJ Glob. Health20238801272510.1136/bmjgh‑2023‑012725 37640493
     [Google Scholar]
  91. GrewalH. SharmaP. DhillonG. MunjalR.S. VermaR.K. Kashyap R. Universal health care system in India: An in-depth] examination of the Ayushman Bharat initiative.Cureus20231564073310.7759/cureus.40733 37485096
     [Google Scholar]
  92. HollingworthS.A. LeaupepeG.A. NonvignonJ. FennyA.P. OdameE.A. RuizF. Economic evaluations of non-communicable diseases conducted in Sub-Saharan Africa: A critical review of data sources.Cost Eff. Resour. Alloc.20232115710.1186/s12962‑023‑00471‑7 37641087
     [Google Scholar]
  93. RaoK.D. MehtaA. KautsarH. Improving quality of non-communicable disease services at primary care facilities in middle-income countries: A scoping review.Soc. Sci. Med.202332011567910.1016/j.socscimed.2023.115679 36731302
     [Google Scholar]
  94. DuboisD.J. Grand challenges in pharmacoeconomics and health outcomes.Front. Pharmacol.20101710.3389/fphar.2010.00007 21713104
     [Google Scholar]
  95. ThomasD. ZachariahS. ReddyY.P. Alvarez-UriaG. Development of pharmacoeconomics guidelines for India.Perspect. Clin. Res.2014529110.4103/2229‑3485.128030 24741488
     [Google Scholar]
  96. YangJ WeiQ YangX JiaoJ YangZ LiF. Assessment and predictive analysis of health professions students’ proficiency in health economics and pharmacoeconomics in Southwest China: A cross-sectional study. BMC Med Educ2024241123910.1186/s12909‑024‑06214‑3 39482631
     [Google Scholar]
  97. GirardinF.R. CohenK. SchwenkglenksM. Durand-ZaleskiI. Editorial: Pharmacoeconomics in the era of health technology] assessment and outcomes research to prioritize resource use,] innovation and investment.Front. Pharmacol.202314121000210.3389/fphar.2023.1210002 37261286
     [Google Scholar]
  98. BennettC.C. HauserK. Artificial intelligence framework for simulating clinical decision-making: A Markov decision process approach.Artif. Intell. Med.201357191910.1016/j.artmed.2012.12.003 23287490
     [Google Scholar]
  99. FleurenceR WangX BianJ Generative AI in Health Economics and Outcomes Research: A Taxonomy of Key Definitions and Emerging Applications, an ISPOR Working Group Report.2024
     [Google Scholar]
  100. KapoorA SharmaR Innovations in pharmacoeconomic modeling: New techniques for evaluating drug value.2023112918
     [Google Scholar]
/content/journals/cdrr/10.2174/0125899775394503250626070441
Loading
The Pharmacoeconomics and its Evaluation in Enhancing the Indian Healthcare System
Current Drug Research Reviews 18, 106 (2026); https://doi.org/10.2174/0125899775394503250626070441
/content/journals/cdrr/10.2174/0125899775394503250626070441
/content/journals/cdrr/10.2174/0125899775394503250626070441
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): equitable healthcare; Indian healthcare system; models; Pharmacoeconomics; resource allocation; tiered pricing

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test